Treatment for Gorham-Stout syndrome with a combination of teriparatide and denosumab.
Osteoporos Int
; 35(4): 727-731, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38062162
ABSTRACT
Gorham-Stout syndrome is an aggressive, non-hereditary, and rare disease affecting bone metabolism. Its etiology and pathogenesis remain elusive. The syndrome manifests with diverse clinical symptoms, often leading to frequent misdiagnoses and presenting challenges in treatment. In this study, we report a case of cranial and maxillary osteolysis in a 47-year-old female patient with somatic mutations in the VEGF-A, VEGF-B, and VEGF-C genes and the EPHB4 gene. After treatment with bisphosphonates, this patient still had persistent resorption of the mandible, but switching to a teriparatide and denosumab combination yielded substantial improvement. This study is the first report to show that teriparatide combined with denosumab can be used to treat Gorham-Stout syndrome.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Osteólise Essencial
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article